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The problem of antibody demonstration in
allergic eezematous contact-type sensitivity has
intrigued dermatologists for many years and has
been subjected to extensive experimental investi-
gation. Passive transfer of allergic contact sensi-
tivity with mononuclear blood cells and lymph
node cells in guinea pigs has been accomplished
with relative ease by many investigators using
diverse technics following the original work of
Landsteiner and Chase and Haxthausen (1, 2, 3,
4). It appeared paradoxical and puzzling that on
the contrary, attempts by Haxthausen (5, 6) and
by Baer, Sulzberger, Serri and Kirman (7, 8) to
transfer allergic cezematous contact-type sensi-
tivity by these same procedures in man have
been nnsuccessful or at best produced equivocal
results.
Recently Epstein and Kligman (9) reported
that they had been successful in passively trans-
ferring allergic contact sensitivity to three contact
allergens in man—3-pentadecylcatechol (PD C),
paranitrosodimethylaniline (NDMA), and 2,4-
dinitrochlorobenzene (DNCB). This was accom-
plished through both intradermal and intravenous
injections of leukocytes from the peripheral
blood of highly sensitive donors. They attributed
the failures of other investigators to the transfer
of insufficient numbers of leukocytes, to inade-
quate sensitivity of the donors of the cells, or to
"admirable conservatism" which kept previous
investigators from claiming that they achieved
passive transfer on the basis of a few positive
results. Epstein and Kligman felt that to achieve
successful passive transfer of DNCB sensitivity
in man at least 170 million lymphocytes must be
injected intradermally or 1 billion intravenously,
from donors sensitive to dilutions as high as
1:1,000,000.
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In view of these positive findings it was decided
to undertake another study on transfer of contact
sensitivity to DNCB, utilizing whole blood
transfusions from donors with exceedingly high
degrees of sensitivity (10).
METRODS AND MATERIALS
The four volunteer donors were white males
hospitalized for chronic dermatoses (atopic
dermatitis, peripheral vascular disease (2 donors),
and allergic contact dermatitis). They were
selected from among 11 hospitalized patients all of
whom had been repeatedly exposed to 2 drops
(0.014 ml) of 10% DNCB in acetone extruded
through a 22 gauge needle onto the subscapular
area at intervals of 1—4 weeks and were found to
be extremely sensitive after one to three such
applications. The four selected for this study
responded to challenges with concentrations of
DNCB as low as .0001%.
The recipients were comprised of seven white
male patients hospitalized on a ward separate
from that of the cell donors to guard against
inadvertent exposure to DNCB. In order to insure
viability of the transferred white cell elements,
phlebotomy and transfusion were so arranged as
to assure completion of the transfer in a mini-
mum period of time. Under sterile conditions,
500 cc of whole blood was collected from the donor
volunteers in a Saftivac® vacuum bottle which
contained 120 cc of "A-C-D Solution 'B' U.S.P.*
Within minutes, the blood was administered to
the compatible volunteer recipient, the elapsed
time from the beginning of phlebotomy to com-
pletion of the transfusion ranging from 22 to 49
minutes. Leukocyte viability counts (11) were
done on several occasions to insure that the
technic was not harmful to a substantial number
of the white cells (Table I).
Twenty-four hours after transfusion the re-
cipients were skin-tested at duplicate symmetrical
sites with 2 drops (.014 ml) of 0.1% and 1 drop of
1% DNCB in acetone on the subscapular area.
These tests were repeated 48 hours following the
transfusion.
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* "A-C-D Solution 'B' U.S.P.": Each 100 cc
contains Sodium Citrate U.S.P. 1. 32 Gm., Citric
Acid U.S.P. (anhydrous) 0.44 Gm., and Dextrose
U.S.P. 1.47 Gm.
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TABLE I
Quantity and viability of leukocytes transferred
Donor
A. N.
P. McT.
J. McC.
D. T.
A. N.
J. MeC.
A. N.
Recipient
H. D.
J. P.
M. L.
F. S.
M. 0.
P. W.
J. J.
Time Elapsed
for Transfer
mm
38
49
34
22
24
32
30
Total Number
uf Leukorytes
Transferred
4.5 X 10
3.5 X 10
8.5 X 10
4.8 x l0
7.5 X 10
9.5 X l0
5.5 X 10
Total Number
of Lymphocytes
Transferred
1.5 >< 10
1.1 X 10
2.1 X l0
2.4 >< 10
2.1 X 10
3.8 X 10
1.8 >< 10
Minimum % uf Viable
Leukorytes after
Transfusion
not determined
not determined
91%
88%
86%
not determined
not determined
TABLE II
Erythema response of F. S. to 1% DNCB
Time Interval of Erythema Readings After 1%
DNCB Application
Immediately 24 hrs. 48 lsrs. 72 hrs. 1 week
DNCB applied 1 day after transfusion
DNCB applied 2 days after transfusion
DNCB applied 7 days after transfusion
+
0
0
++
+
+++*
+
+
++
+
0
++'
0
0
0
* Edema noted; 0.1% DNCB also positive.
RESULTS AND COMMENTS
None of the 7 recipients reacted to 0.1%
DNCB solution in acetone applied 24 and 48
hours following the transfusion. Two of the 7
recipients developed erythema at the sites tested
with 1% DNCB solution. In one recipient, F. S.,
who developed a moderate erythematous response
without edema (Table II) when tested with 1%
DNCB 24 hours after transfusion, there was a
pronounced decrease in erythema when tested 48
hours following the transfusion. In the only other
patient manifesting a positive response to 1%
DNCB, the intensity of erythema was the same
when the test was repeated 48 hours later.
In order to permit proper evaluation of the
erythematous response to 1% DNCB in 2 of the
7 cell recipients, a group of 8 volunteers who had
no known previous exposures to DNCB were
tested with the 1% solution in a manner identical
to all recipients. Two of this group responded
with unequivocal erythema without edema.
DISCUSSION
In the series of tests reported here we tried to
avoid the 3 principal pitfalls which may have
caused previous failures (4, 5, 6) to passively
transferred eczcmatous contact-type sensitivity.
These arc 1) inadequate sensitivity of the donor;
2) inadequate number of cells transferred and 3)
poor or absent viability of the cells transferred.
Despite the usc of what we believed to be proper
tcchnics to avoid these pitfalls, all of the 7 recipi-
ents, each of whom received at least 1 billion
lymphocytes from donors hypersensitive at
least to a 1:1,000,000 DNCB solution in acetone,
wore uniformly negative in response to challenge
with 0.1% DNCB. It is somewhat difficult to
harmonize the unsuccessful passive transfer in
these cases with the positive findings of Epstein
and Kligman in 2 out of 2 recipients of intra-
venously administered donor white cells. How-
ever, differences in the technic of testing may
help to explain the discrepancies. Our procedure
was to place 2 drops of 0.1% DNCB on each
skin site and then to permit acetone to evaporate
at room temperature actually leaving approxi-
mately 0.014 mg DNCB per test site. Epstein and
Kligman (12) challenged their cell recipients by
placing 0.25 ml of a 0.1% DNCB solution in an
open end glass cylinder, 2.9 cm in diameter, which
was placed against the skin test site. They then
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PLUTJi ITT
Epstein and Kligman. .. DNCB
Harbor and Baer DNCB
Epstein and Kligman.... DNCB
Meneghini and Levi pot. dichromate
Mono ghini and Levi turpentine
Meneghini and Levi nickel sulfate
permitted the acetone to evaporate. Thus they
actually tested their site with 0.25 mg of DNCB.
Although it would be almost impossible to
accurately state what size skin area the 2 drops
of our solution covered as it rapidly spread on
the skin surface, there can be no doubt that
Epstein and Kligman deposited locally on a
given area of skin surface approximately 17 times
as much allergen as we did. Obviously then they
applied almost twice as much DNCB to each
site in their tests with 0.1% DNCB than we did
in our test sites with 1% DNCB.
It is therefore likely that Epstein and Klig-
man's positive results with 0.1% DNCB should
be considered together with our positive skin tests
to 1% DNCB in two of our 7 cell recipients.
Our experience and that of previous workers
suggests that a concentration of 0.14 mg of
IDNCB per test site may well be at the borderline
of primary irritancy. This is evident also from
the response of mild or moderate crythema in 2
of the 8 control volunteers who were drop tested
in a manner identical to the cell recipients. In
one of these cases the crythcma did not appear
until 12 hours following application and persisted
48 hours.
In spite of these results it cannot be entirely
ruled out that a transfer of specific sensitivity
may have been accomplished in one of our cases
(Table II). This patient had moderate erythcma
when challenged with 1% DNCB 24 hours follow-
ing transfusion and only slight erythema when
the test was repeated the following day. Six
days after the original test 1% DNCB was
applied again and a positive response, accom-
panied by edema was elicited. Furthermore
a positive response to 0.1% DNCB was noted for
the first time. This was interpreted as indicating
X 10-D.5 x 10 10 3
X 105.0 x 10 9 0
X 10—1.6 X 10 2 0
X 10-1.6 x 10 2 0
that active sensitivation had taken place due to
the exposures to 1% DNCB used in the previous
skin tests.
It is of interest to note that recently Meneghini
and Levi (13), (Table III) failed in their attempts
to passively transfer allergic hypersensitivity to
common contact allergens including chromatc,
nickel and sulfonamide. They used quantities of
leukocytes from the circulating blood and from
lymph nodes ranging from 100 million to 500
million, administered to the recipients by intra-
dermal injection. More recently Scrri (14) has
attempted to transfer DNCB sensitivity. His
technic involved 3 daily transfusions of 30—40
cc of citratcd whole blood from highly sensitized
donors. The recipients were then challenged 1, 2,
4 and 6 days following the last transfusion with
0.25% DNCB. Serri too, reported no evidence
of successful passive transfer.
The possibility still remains that through
modification of technics it will be possible to
develop a method which will consistently permit
demonstration of the hypothetical antibody of
allergic eczematous contact sensitization. This
would seem likely to succeed in view of the
success of Lawrence (15) and others with transfer
of tuberculin sensitivity in man.
However it is by no means established to what
degree human tuberculin-type skin sensitivity
and human cczcmatous contact-type sensitivity
to simple chemicals are related and to what degree
they differ, either immunologically or otherwise.
However our results suggest that it would be
worthwhile to explore further the possible differ-
ences as well as the similarities.
Furthermore the fact that DNCB sensitivity
in guinea-pigs can be transferred by means of
white cell suspensions while our experiments did
Passive transfer of peripherat btood len/roe ytes ______
Compound
Average No. of Range no. otLymphocytes Recipients Transfers
x 10—1.3 X 10
x 10—3.S X 10
Intravenous
1.0 x
2.1 X
Intradermal
4.7><
2.5 1<
1.6 1<
0.7 1<
Injection
10 1.0
10 1.1
Injections
10 1.7
10° 1.0
10° 1.5
10 1.6
3 2
7 0
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not succeed in doing this in man suggests the
possibility of significant differences in these
forms of sensitivity and the mechanisms mediat-
ing them.
SUMMARY
1. Passive transfer of allergic eezematous
contact sensitivity to DNCB was attempted in 7
patients. The technic used involved blood trans-
fusions each of which contained at least one
billion viable mononuclear cells from donors
exquisitely sensitive to DNCB.
2. No transfer was demonstrated. None of the
recipients reacted to challenge with 0.1% DNCB.
Two of the 7 recipients had positive reactions to
1% DNCB. The significance of these responses is
discussed. It is pointed out that DNCB in 1%
concentrations approaches the borderline of
primary irritaney.
3. The results suggest that there may well be
significant differences between tuberculin-type
and contact-type eczematous sensitivity in man
and also between contact-type eezematous sensi-
tivity in man and guinea pigs.
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DISCUSSION
DR. WILLIAM L. EPSTEIN (San Francisco,
Calif.): I commiserate with my colleagues; there
is nothing more discouraging than negative
results and in a procedure that is as difficult to
perform as passive transfer it is especially frus-
trating. I would like to point out that we are not
the only ones who have transferred sensitivity
to DNCB and DNFB in man. Robert Good at
approximately the same time as we reported
transfer of delayed hypersensitivity to dinitro-
chlorobcnzcne in patients with hypogamma-
globuliacmia. Subsequently Charles Calnan from
England working at the University of Pennsyl-
vania also was able to transfer sensitivity to
dinitrochlorobenzcnc in man.
The technics of Dr. Harbcr and Dr. Baer are
somewhat different from the methods we used.
Besides having very sensitive donors and using
the intravenous method of transmitting large
numbers of lymphocytes, our subjects were
healthy young males. Dr. Harber's were hospi-
talized; obviously they were there for a reason.
My experience with hospitalized patients suggests
that they do not react as briskly as active persons.
Another point of difference is our testing method.
We applied greater amounts of allergen to the
skin. The concentrations used were borderline
irritating but with experience it was possible to
distinguish irritant and allergic reactions to
DNCB; the prime points of distinction are delay
in onset of allergic reactions and duration of the
response. When dealing with very weak allergic
reactions, as many of the transferred sensitivities
are, it is vital to use the greatest amount of
allergen possible in order to elicit a measurable
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response. The answer is to have a wide experience
with the chemicals in question.
Finally, I would like to suggest that Drs.
ilarber and Baer might have more luck trans-
mitting sensitivity to pentadecyl catechol. There
is a very important point here. Transmission of
most simple chemical hypersensitivity in man is
very difficult whereas the transfer of sensitivity
to poison ivy and fungal and bacterial agents is
relatively simple. Previous exposure to these
latter substances may in some way facilitate
transfer without actually sensitizing the subject.
I am suggesting that an altered state of reactivity
exists in the subject in whom transfer is success-
ful. In America nonsensitive adults cannot be
sensitized to Rhus allergens but children are
readily sensitized by even minimal exposure
(Epstein, W. L.: Rhus dermatitis, Ped. Clin. N.
Amer. 6: 843, 1959).
Dn. ALBERT M. KLIGMAN (Philadelphia,
Pa.): The American-British philosopher White-
head once remarked, "A conflict is not by any
means a catastrophe. It is an opportunity for
enlightcnment.'
I feel very much in that mood as I think of
what has happened here. Without taking sides in
the matter, there is something very peculiar about
this question of transferring delayed type sensi-
tivity with leukocytes. The fact is that it is rather
easy to do when one uses antigens which are
native to the environment of the recipients.
Sherwood Lawrence in New York City finds it
almost impossible not to transfer tuberculin
sensitivity no matter what he does to the donor
leukocytes.
In our own work it was rather easy to transfer
delayed sensitivity to the poison ivy antigen to
which the recipients could have been presumed to
have had some previous natural exposure.
Similarly they have probably had a minor skir-
mish with the tubcrcle bacillus. The point here is
that the recipients are not virgins with respect
to these antigens. Passive transfer in such
instances may be simply elevation of latent sensi-
tivity to a clinical level. Now transfer of dinitro-
chlorobenzene sensitivity is quite another
matter. This substance is novel to the recipients
and passive transfer very difficult to accomplish.
Calnan in our laboratory last year went
through a very considerable exercise to try to
increase the efficiency of dinitrochlorobenzene
transfer but most of his efforts were futile. It is
a tough thing to do and one has to be extremely
meticulous in all details.
DR. MARION B. SULzBERGER (New York,
N. Y.): First of all I would like to second what
Dr. lKligman has just said and emphasize once
again that most of the regular successes in passive
transfer of contact-type cczematous sensitivity
in man have been with "antigens" with which
the recipient individual can be presumed to have
had the possibility of some previous contacts. The
question then arises whether one is really per-
forming a passive transfer of antibodies. Maybe
one is just producing a "booster effect," an
"anamncstic response".
It is quite conceivable that the transferred
donor cells may contain traces of potent or
coupled antigen sufficient to produce a powerful
booster effect in recipient individuals with a
prc-existing very low level of sensitivity. This
explanation would fit in well with all of the
time sequences observed; and also with the
phenomenon that the sensitivity often generalizes
all over the skin surface even when the cells are
deposited only in one small site. The hypersensi-
tivity does not remain local as it does, for
instance, when one puts other types of antibodies
such as Prausnitz-Kuestncr rcagins into a skin
site. All these phenomena and still others make it
appear to me that this may not actually be a
passive transfer which one is accomplishing with
the donor cells. Ones must have what Kligman
so picturesquely described as a "virgin soil" in
the recipients in order to be sure that the transfer
has been a passive one through transfer of anti-
bodies and not an active booster effect through
addition of antigens. I admit, however, that
there are many things about this situation that
arc not quite as simple as I have just expressed
them.
In many discussions with Sherwood Lawrence,
who works at our school, we have speculated
about the possibility that these phenomena
produced by cell transfers arc due to booster
effects. I suggested that he try sensitizing individ-
uals with cells of donors that were sensitive to
antigens to which the recipients had never been
exposed. lie recently used cells from coccidioidal
granuloma patients in California who were skin
sensitive to Coccidiomycin; and with transfer
of these cells he was able to produce positive
Coccidiomycin skin test sensitivity in some (but
not all) recipients in New York City who pre-
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sumably had had no previous exposure to the
eoeeidioidal antigen itself.
The other thing I would like to emphasize
before I sit down is that, just as stated by Harber
and Baer, I am afraid that Kligman and Bill
Epstein were working with borderline irritant
concentrations in their skin tests with dinitro-
ehlorobenzene. They applied so much dinitro-
chlorobenzene per unit of skin area that it was
on the border of primary irritaney; therefore in
any reactions which they saw after applications
of their material it would he extremely difficult
if not impossible to distinguish between possible
primary irritant effects and possible passively
transferred allergic eczematous sensitivity.
DR. LEONARn C. HARnER (in closing): Dr.
William Epstein's remarks raised several valid
points which illustrate the difficulties involved in
interpreting data concerning cellular transfers of
allergic eczematous contact-type allergy. Dr.
Good did claim to have positive results in cell
transfers of dinitrofiuorobcnzenc (DNFB) sensi-
tivity. On the other hand, Dr. Serri attempted to
transfer DN CE sensitivity with essentially the
same technics as Dr. Epstein and Dr. Kligman had
described in their report. His attempts as well as
ours which I described today were not successful.
I believe the DNCB concentration which Dr.
Serri used for skin testing was 0.25%.
With respect to age and physical condition of
the patients at Bellevue Hospital who were used
as donors, they did come from a relatively low
socio-economic status. Their ages ranged from 17
to 00. However, all of these volunteers were
carefully examined before they gave whole blood
in order to assure that this would not be a detri-
ment to their health and the same is also true of
the recipients of the whole blood transfusions.
Regarding the amount of allergen deposited at
a given site using the technics which we described
as compared with those of Dr. Kligman and Dr.
Epstein, I can best express it in this manner:
a truly positive response observed through our
drop testing procedure consisted of an erythe-
matous reaction about 2.5 cm. in diameter.
Obviously the .014 milliliter of acetone which is
initially dropped on the skin is unlikely to cover
a 2.5 em. area. It is the result of diffusion. As
far as trying to prevent this by using a cup, as
Dr. Epstein described, we felt that our method
was preferable for the following reasons: first,
it is the method commonly used in this type
of experiment in man and guinea pigs; and
secondly, it avoids the error of depositing primary
irritant quantities of allergen on the skin; and
thirdly, one does run the danger of altering the
physiology of the normal skin site tested by
pressure or prolonged exposure to a solvent.
Commenting on some of Dr. Kligman's
pertinent remarks, we used DNCB instead of
pentadccylcateehol mainly because with this
compound it is always difficult to be sure that the
recipient of the transfer cells was not previously
sensitized by natural exposure to poison ivy.
In addition, when one does a test before the
transfer experiment to make sure that an individ-
ual is not already hypersensitive to the allergen
which one intends to use, one can justly be criti-
cized that the test dose itself acted as the sensi-
tizing dose that produced the positive results in
the transfer test. It was with this in mind that
we definitely kept all individuals who were going
to be recipients of DNCB on a different ward than
that of the donors who were being sensitized to
DNCB. With the use of this procedure, we felt
relatively safe in assuming that the recipients
had never encountered 2, 4-dinitrochlorobcnzenc
before they received the whole blood transfusion.
